Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead of the planned 2026 IND filing.
Stocks · News reference
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new preclinical data independently
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ernexa Therapeutics shares are trading higher after the company announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition.
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while health care stocks fell 0.4%. Morgan Stanley beat earnings.